Astellas Pharma Inc.

Maxygen Reports Third Quarter 2009 Financial Results.(Financial report)
Blood Weekly; 11/19/2009; 1222 words; ...period in 2008 (see also Maxygen, Inc.). As described below, the...company's joint venture with Astellas Pharma Inc., and Maxygen's subsequent...Financial, Investing, Technology, Astellas Pharma Inc., Bayer Healthcare AG, Biotechnology...

Aradigm Announces Third Quarter 2009 Financial Results.(Financial report)
Biotech Week; 11/18/2009; 1285 words; ...the collaboration with Lung Rx, Inc. ("Lung Rx") for the development...commercialization by Zogenix, Inc. ("Zogenix") of SUMAVEL* DosePro...S. by Zogenix and its partner, Astellas Pharma US, Inc. We are continuing in our efforts...

Astellas Pharma Europe Announces the International Foundation for Dermatology a Winner of the Changing Tomorrow 2009 Awards.
Biotech Week; 11/18/2009; 607 words; Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma Inc, one of the world's top 20 pharmaceutical...other childhood diseases. Keywords: Astellas Pharma Inc., Dermatology, Pharmaceutical Business...

Seattle Genetics Initiates Phase I Clinical Trial of Antibody-Drug Conjugate SGN-75.
Business Wire; 11/16/2009; 1296 words; BOTHELL, Wash. -- Seattle Genetics, Inc. (Nasdaq: SGEN) today announced that it has initiated...development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics...

XenoPort to Release Third Quarter Financial Results on November 3, 2009.(Financial report)
Investment Weekly News; 11/14/2009; 786 words; XenoPort, Inc. (Nasdaq: XNPT) announced that it...38475337. About XenoPort XenoPort, Inc. is a biopharmaceutical company focused...candidate, XP13512, in collaboration with Astellas Pharma Inc. and GlaxoSmithKline (GSK). The Food...